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In April 2006, Japan’s health insurance system instituted a
bundling policy that included recombinant human
erythropoietin (rHuEPO) in outpatient hemodialysis therapy.
To evaluate outcomes of this, we analyzed a prospective
cohort of hemodialysis patients in the Japan Dialysis
Outcomes and Practice Patterns Study, in 53 facilities using
prevalent cross-sections of 1584 patients before and 1622
patients after the rHuEPO reimbursement change. Patient
data included hemoglobin levels, iron management profiles,
and anemia treatment with rHuEPO and intravenous iron. No
significant differences were found in pre- or post-policy
cross-sections for hemoglobin distributions or the
percentage of patients prescribed rHuEPO. Among patients
receiving rHuEPO, the mean dose significantly decreased by
11.8 percent. The percentage of patients prescribed
intravenous iron over 4 months significantly increased;
however, the mean dose of iron did not significantly change.
Thus, this bundling policy was associated with reduced
rHuEPO doses, increased intravenous iron use, and stable
hemoglobin levels in Japanese patients receiving
hemodialysis.
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Anemia of chronic kidney disease is mainly caused by relative
deficiency of endogenous erythropoietin (EPO) production
and is a very common complication of late-stage chronic
kidney disease.1 Therefore, the availability of recombinant
human erythropoietin (rHuEPO) analogs, also known as
erythropoietin-stimulating agents (ESAs), has had important
implications for clinical practice. The introduction of
rHuEPO in 1989 led to substantial rises in hemoglobin
(Hb) levels among end-stage renal disease (ESRD) patients2
and reduced the need for blood transfusions.3 However,
several large randomized clinical trials have demonstrated a
trend toward increased mortality, or no difference in
mortality, in either ESRD or chronic kidney disease patients
receiving ESAs targeted to higher Hb levels (X13 g/dl) than
those currently recommended in clinical guidelines.4–8
Furthermore, some studies suggest that higher ESA doses
may partially be responsible for the apparent elevation in
mortality and morbidity risk associated with the higher
Hb targets.5,9
Hemoglobin levels and doses of rHuEPO given to
hemodialysis (HD) patients have both risen substantially
since the introduction of rHuEPO.10,11 The rHuEPO
reimbursement policies in both Japan and the United States
were, for many years, based on a fixed payment per dose.
In the United States, rHuEPO now comprises nearly 10%
of all Medicare costs for ESRD patients.10 In Japan,
rHuEPO payment was fixed per dose until 1 April 2006,
and the annual expenditure on rHuEPO before this date was
6% of the total ESRD costs.12 Thereafter, an rHuEPO
bundling policy was initiated for outpatients, such that
rHuEPO was not separately billable on a per-dose basis,
but instead bundled within overall reimbursement for
dialysis services.
In this study, we analyzed data from a representative
cohort of HD patients in the Japan Dialysis Outcomes and
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Practice Patterns Study (JDOPPS) to investigate the change
in anemia treatment practice patterns—including rHuEPO
dosing, intravenous (IV) iron use, and laboratory measures
of iron stores—from before to after the newly introduced
rHuEPO bundled reimbursement policy. We also evaluated
practice changes according to different types of HD facility
ownership.
RESULTS
Table 1 shows that patient characteristics were generally
consistent across cross-sections. The mean age was 62.2 years
in January 2006 and 63.0 years in January 2007. Mean HD
vintage (duration of ESRD) increased from 8.3 to 8.4 years
between the cross-sections. There was no marked change in
the prevalence of 13 summary comorbidities over the cross-
sections.
Patient Hb distributions by cross-section are shown in
Figure 1. No notable differences were observed in the earlier
versus later cross-sections for the mean Hb (10.39 g/dl in
January 2006 vs 10.38 g/dl in January 2007; P¼ 0.80) or
median Hb (10.40 g/dl at both times). The overall distribu-
tions changed only slightly, with fewer patients having Hb
X11 g/dl (from 32.4 to 29.5%; P¼ 0.06), but slightly higher
mean Hb for patients with Hb X11 g/dl (from 11.74 to
11.86 g/dl).
Figure 2 shows the distribution of rHuEPO doses in each
cross-section. The percentages of HD patients prescribed
rHuEPO were 81.9 and 82.2% in January 2006 and January
2007, respectively (P¼ 0.75). Among patients prescribed
rHuEPO, there were 93 patients whose average weekly dose
was set to missing because of rHuEPO dose record or was out
of the plausible dose range (o750 or 49000U per week):
n¼ 46 (2.9%) and n¼ 47 (2.9%) for January 2006 and
January 2007, respectively. Those patients were not con-
sidered in calculation of the overall mean rHuEPO dose. The
rHuEPO dose decreased from 5266U per week in January
2006 to 4645U per week in January 2007 (by 11.8%;
Po0.001). When analyzed as categories of rHuEPO dose
(44500U per week, 3000–4500U per week, 750–2999U per
week, and not prescribed rHuEPO), the distribution of
rHuEPO doses was also different (Po0.001) between the two
cross-sections.
The distribution of IV iron dosing by cross-section is
shown in Figure 3. The percentage of patients prescribed IV
iron increased from 31.8% in January 2006 to 41.2% in
January 2007 (þ 9.4%; Po0.001). In addition, there were
29 patients prescribed IV iron who had an average monthly
dose that was missing: n¼ 15 (0.9%) and 14 (0.9%) for
Table 1 | Patient characteristics by cross-section
Mean (s.d.) or percentage
Patient characteristic
January 2006
(n=1584)
January 2007
(n=1622)
Demographics
Age (years) 62.2 (12.2) 63.0 (12.0)
Male 60.7 61.3
Time on ESRD (years) 8.3 (7.1) 8.4 (7.3)
New to dialysisa 0.9 1.2
Comorbidities
Coronary artery disease 40.6 40.1
Congestive heart failure 24.4 24.7
Other cardiac disease 32.9 31.9
Diabetes 32.3 33.5
Hypertension 73.2 74.7
Cerebrovascular disease 12.8 12.5
Peripheral vascular disease 17.6 16.6
Cancer (other than skin) 9.2 9.7
Lung disease 2.5 2.4
History of GI bleed 4.2 4.0
Neurological disease 9.1 7.8
Psychiatric disorder 3.4 3.4
Recurrent cellulitis/gangrene 4.4 3.2
Abbreviations: ESRD, end-stage renal disease; GI, gastrointestinal.
aPatients joining Dialysis Outcomes and Practice Patterns Study within 30 days of
first-ever dialysis.
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Figure 1 |Distributions of hemoglobin levels by cross-section.
Intervals areo8, 8 too9, 9 too10, 10 too11, 11 too12, 12 to
o13, and X13 g/dl.
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Figure 2 |Distributions of recombinant human erythropoietin
(rHuEPO) doses by cross-section. Overall percentage of patients
prescribed rHuEPO in January 2006 was 81.9% and in January
2007 was 82.2% (P¼ 0.75). Among patients prescribed
erythropoietin (EPO), the mean dose was 11.8% lower after
bundling (Po0.001). The distribution of rHuEPO dose (as captured
by the four categories in the figure) also differed between cross-
sections (Po0.001).
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January 2006 and January 2007, respectively. The overall
mean IV iron dose among HD patients prescribed IV iron did
not differ substantially in the two cross-sections (105mg per
month in January 2006 vs 111mg per month in January
2007; P¼ 0.15). However, the IV iron dose distribution
differed (Po0.001) between the cross-sections when treated
as a categorical variable (X150mg per month, 100–149mg
per month, 50–99mg per month, 1–50mg per month, and
not prescribed IV iron).
The distributions of serum transferrin saturation (TSAT)
and ferritin levels by cross-section are presented in Figures 4
and 5. Mean TSAT rose from 26.0% in January 2006 to 27.9%
in January 2007 (þ 1.9%). The percentage of patients with
TSAT o20% decreased from 36.0 to 28.8% (7.2%),
whereas the percentage with TSAT X40% increased from
12.7 to 17.2% (þ 4.5%). Mean serum ferritin levels were
nearly unchanged between the cross-sections (222 ng/ml in
January 2006 vs 224 ng/ml in January 2007). However, the
percentage of patients with ferritin o100 ng/ml decreased
from 52.6 to 41.3% (11.3%) and the median ferritin levels
increased from 89 to 132 ng/ml, suggesting an overall increase
in iron repletion of HD patients due to additional iron
provision after implementation of the rHuEPO bundling
policy.
Table 2 provides trends of anemia treatment and iron
management profiles according to Hb strata of o11 and
X11 g/dl. Similar reductions of rHuEPO doses were observed
in the higher and lower Hb groups. The mean dose of
rHuEPO decreased from 4455U per week to 4125U per week
(þ 7.4%; P¼ 0.01) in the higher Hb stratum and from
5579U per week to 4803U per week (þ 13.9%; Po0.001) in
the lower Hb stratum. Among patients with Hb o11 g/dl or
X11 g/dl, the percentage of patients prescribed IV iron
increased over the cross-sections (from 30.6 to 41.9%
(þ 11.3%; Po0.001) and from 34.1 to 40.6% (þ 6.5%;
P¼ 0.02), respectively). The percentages of patients with
TSAT o20% and ferritin o100 ng/ml decreased similarly in
the higher and lower Hb groups.
In Table 3, we show change in rHuEPO and IV iron dosing
from January 2006 to January 2007 by the type of facility
ownership (private clinics, private hospitals, and public
hospitals). The change in the percentage of HD patients on
rHuEPO differed by type of ownership: the percentage on
rHuEPO decreased in the private clinics (1.5%; P¼ 0.13)
and public hospitals (1.5%; P¼ 0.14), but increased in
private hospitals (þ 5.2%; P¼ 0.03). The mean doses of
rHuEPO decreased consistently in each facility ownership
type over the cross-sections: by 12.1% in the private clinics
(Po0.001), by 13.7% in the private hospitals (Po0.001), and
by 8.8% in the public hospitals (P¼ 0.002). The percentage
of patients prescribed IV iron increased across facility type,
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Figure 3 |Distributions of intravenous (IV) iron doses by
cross-section. Overall percentage of patients prescribed IV iron in
January 2006 was 31.8% and in January 2007 was 41.2%
(Po0.001). Among patients prescribed IV iron, mean doses rose
6mg/month (P¼ 0.15). The distribution of IV iron prescription (as
captured by the five categories in the figure) also differed
between cross sections (Po0.001).
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Figure 4 |Distributions of transferrin saturation (TSAT) by
cross-section. Intervals are o10, 10 to o20, 20 to o30, 30 to
o40, 40 to o50, and X50%.
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Figure 5 |Distributions of ferritin by cross-section. Intervals are
o50, 50 to o100, 100 to o200, 200 to o300, 300 to o400, 400
to o500, and X500 ng/ml.
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but was more remarkable in the private clinics (þ 8.6%;
Po0.001) and hospitals (þ 14.6%; Po0.001) than in the
public hospitals (þ 4.3%; P¼ 0.24). The change in mean
monthly IV iron dose was similar across facility types.
DISCUSSION
The Japanese government introduced an rHuEPO bundling
policy for outpatient HD patients in April 2006 with the aim
to curtail overall dialysis payments by 4%. With this rule,
outpatient ESA reimbursement changed from a fixed
payment per units of administered rHuEPO to a payment
that included rHuEPO independent of its dose (bundling).
Payment for each dialysis treatment was increased by
2900 yen (B30 US dollars), irrespective of rHuEPO use.
In this study, using two cross-sections of HD patients in
JDOPPS, we investigated the shift in anemia treatment
practice patterns before versus after the April 2006 change in
outpatient ESA reimbursement. Data from the cross-sections
before and after the change in rHuEPO reimbursement
indicate that the distribution of Hb levels was essentially
unchanged (Figure 1). Although the percentage of patients
on rHuEPO did not change appreciably, the overall mean
rHuEPO doses among the 82% of patients treated with
rHuEPO decreased by 11.8% (Figure 2). The overall
percentage of patients prescribed IV iron increased by 9.6%
between the cross-sections (Figure 3).
Longitudinal trends in anemia management practices in
Japan before the new ESA reimbursement policy of April
200613 need to be considered when comparing data from
January 2006 with that from January 2007. Akizawa et al.
Table 2 | Trends of anemia treatment and iron management profiles, overall and by Hb levels
Overall Hemoglobin o11 g/dl Hemoglobin X11g/dl
Measure 2006 2007 2006 2007 2006 2007
Number of patientsa 1584 1622 1054 1133 504 473
rHuEPO use
Patients on rHuEPO (%) 81.9 82.2 89.0 89.9 68.8 65.5
Mean dose (U per week) 5266 4645b 5579 4803b 4455 4125c
Percentage change in dose 11.8% 13.9% 7.4%
IV iron use
Patients on IV iron (%) 31.8 41.2b 30.6 41.9b 34.1 40.6c
Mean dose (mg per month) 105 111 95 109c 123 117
Measures of iron stores
TSAT (mean, %) 26.0 27.9b 25.1 27.7c 27.7 28.5
TSAT o20% (%) 36.0 28.8c 38.2 28.8c 32.0 29.1
Ferritin (mean, ng/ml) 222 224 240 238 182 187
Ferritin o100 ng/ml (%) 52.6 41.3b 52.3 39.0b 53.0 47.2d
Abbreviations: Hb, hemoglobin; IV, intravenous; rHuEPO, recombinant human erythropoietin; TSAT, transferrin saturation.
aPatient numbers by Hb levels does not equal overall number because of missing Hb values (n¼ 26 and 16 for January 2006 and January 2007, respectively).
bPp0.001 vs January 2006 value.
c0.001oPp0.05 vs January 2006 value.
d0.05oPp0.10 vs January 2006 value.
Table 3 | Trends of anemia treatment and iron management profiles, by facility ownership type
Private clinics
(n=27 facilities)
Private hospitals
(n=14 facilities)
Public hospitals
(n=12 facilities)
Measure 2006 2007 2006 2007 2006 2007
P-value for
interactiona
Number of patients (n) 824 837 440 464 320 321 —
Hemoglobin (g/dl) 10.40 10.33 10.58 10.49 10.13 10.36b 0.01
rHuEPO use
Patients on rHuEPO (%) 80.5 79.0 78.4 83.6b 90.3 88.8 0.01
Mean dose (U per week) 4879 4287c 5347 4615c 6063 5528b 0.65
Percentage change in dose 12.1% 13.7% 8.8%
IV iron use
Patients on IV iron (%) 28.9 37.5c 34.1 48.7c 35.9 40.2 0.10
Mean dose (mg per month) 113 119 95 104 102 108 0.92
Abbreviations: IV, intravenous; rHuEPO, recombinant human erythropoietin.
aP-values for interaction between changes in each measure and ownership type.
b0.001oPp0.05 vs January 2006 value.
cPp0.001 vs January 2006 value.
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described that mean Hb level rose from 9.7 g/dl (1999) to
10.1 g/dl (2002) to 10.4 g/dl (2006) (Po0.0001). That change
was likely, in part, due to the clinical guidelines for renal
anemia of ESRD patients released by the Japanese Society for
Dialysis Therapy (JSDT) in 2004.14 Our data indicate that
the mean Hb level had stabilized before implementation
of the bundle in 2006 (mean Hb¼ 10.5 g/dl in 2005). The
percentage of patients prescribed rHuEPO and IV iron were
83 and 32%, respectively, and both remained constant in the
7-year (1999–2006) observation period. Similarly, mean
rHuEPO doses did not change substantially during the
years preceding the policy change (5176U per week in 2002
to 5231U per week in 2006).13 Thus, the observed trends
from pre- to post-policy change do not appear to be
explained by continuation of a prior trend in anemia
management.
We looked for concurrent changes in case mix and
observed no difference in mean patient age or comorbidity
burden among Japanese HD patients over the cross-sections
in this investigation (Table 1). Therefore, the decrease in
mean rHuEPO dose and increase in percentage of patients
prescribed IV iron were likely mostly attributable to the
newly introduced rHuEPO reimbursement policy.
These rHuEPO doses and Hb levels are markedly lower
in Japan than in Western countries, as shown by the Dialysis
Outcomes and Practice Patterns Study (DOPPS).15–17
Differences are largely because of Japanese practice guide-
lines, the rHuEPO package insert, and the reimbursement
policy. The 2004 JSDT guideline is most relevant to the
current publication, as the guideline was next updated in
2008 (after the study period). The 2004 JSDT guideline for
renal anemia in HD patients recommended a target Hb of
10–11 g/dl for most HD patients and 11–12 g/dl for relatively
younger active HD patients.14 It indicated that rHuEPO
should be injected (IV) through the dialysis circuit because of
concerns about the onset of pure red cell aplasia. Until these
guidelines were released, Japanese physicians had generally
adhered to the targeted Hb level according to the rHuEPO
package insert in Japan (B10 g/dl). The maximum dose of
rHuEPO has been limited to 9000U per week for HD
patients by the Japanese package insert and (until April 2006)
by Japanese reimbursement policy. Additionally, Akizawa
et al.13 reported that 490% of pre-dialysis session blood
samples in Japan were drawn in the supine position and at
the first dialysis session of the week, and that these may partly
account for the lower reported Hb levels than that observed
in the other DOPPS participating countries.
Japanese HD patients were also least likely to be prescribed
IV iron among the 12 DOPPS countries.15–17 The 2004 JSDT
recommendation for the target iron profiles are more
conservative (TSAT 420%, serum ferritin 4100 ng/ml)
than some other countries’ guidelines.18,19 The criteria for
starting iron administration was TSAT o20% or serum
ferritin o100mg/ml, with iron preparation IV injected. The
recommended iron administration regimen is as follows: iron
preparation of 40mg is administrated for a total of
13 consecutive dialysis treatments or once weekly for
3 months. The JSDT guideline does not set the upper limit
of iron indices. It recommends transient, rather than
continuous (‘maintenance’), administration only in the
presence of iron deficiency, considering the risk of iron
overload more sensitively in the Japanese setting such as
greater prevalence of patients with hepatitis C and with
longer HD vintage compared with other countries, etc. This
may be one of the barriers to more liberal IV iron use in
Japan. Despite these conservative management practices
for renal anemia, the mortality rate of HD patients in Japan
has been the lowest among the 12 DOPPS countries.20,21
The hypothesis that the anemia management response to
bundling differed by the type of HD facility ownership was
partly supported by this study. Whereas the mean rHuEPO
dose fell similarly in all three facility types, the percentage of
patients treated with rHuEPO increased in private hospitals
and decreased in other facility types. The increase in the
proportion of HD patients on IV iron was somewhat larger in
private clinics and private hospitals than in public hospitals
over the cross-sections. No international data on similar
policy changes are currently available; however, practice
differences by type of HD facility ownership have been
described in the United States. The US Renal Data System
data has shown large variations in rHuEPO doses among HD
facilities, and that large for-profit chain facilities prescribed
higher rHuEPO doses with higher achieved Hb levels than
non-profit facilities.22 Similarly, exceeding the target Hb
levels recommended by National Kidney Foundation–Kidney
Disease Outcomes Quality Initiative guidelines in 200623 (11
to o13 g/dl) was more common in for-profit facilities than
in non-profit ones.24 However, in general, for-profit health-
care providers are prohibited in Japan. Japanese dialysis
facilities are divided into public hospitals (for example,
national hospitals, municipal hospitals, or semipublic entities
such as universities or the Red Cross Society), private
hospitals, and solo practice (private) clinics. Some private
hospitals and clinics are owned and operated by large dialysis
chains in Japan, but they are not ‘truly for profit’ entities.
Therefore, it is difficult to compare the differences in
practice patterns among provider types between Japan and
the United States.
The clinical impact of changes in anemia management
over this time period in Japan remains unknown. Beyond
regulation of red blood cell production, pleiotropic effects of
ESAs have been identified as possible explanations for
potential benefit or harm of supraphysiological ESA dosing.
With respect to IV iron, several past studies have shown that
its use can reduce average rHuEPO dose.25,26 Moreover,
recent investigations indicated that IV iron therapy raised Hb
levels and improved rHuEPO responsiveness in HD patients
with low TSAT, even when serum ferritin was elevated.27,28
Meanwhile, avoiding iron overload may be necessary to
prevent potential adverse effects such as exacerbation of
infection29 including hepatitis C.30 Although the possibility
of increased risk with increased IV iron therapy merits
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additional study, the observed increase of IV iron given, as
well as the rise in serum TSAT and ferritin levels, were
relatively small in this observation period.
As a potential limitation, JDOPPS dialysis facilities
may not perfectly reflect national data. However, JDOPPS
prospectively collected data using stratified random selection
of facilities to be nationally representative and random
selection of patients within facilities to reduce data collection
burden. Of the 60 facilities selected, 88% (53 facilities)
contributed data for the time frame of these analyses.
Although the secular trends that we have observed are likely
attributable to bundling, we cannot rule out other causes of
change in clinical practice. It is also possible that additional
changes in response to the April 2006 rHuEPO bundling
policy will occur beyond our median follow-up date of
January 2007. Moreover, we suggest caution when applying
the findings in Japan to predict changes in practice and Hb
levels in other countries (for example, in response to ESA
bundling in the United States, which is anticipated in 2011),
because Hb values and ESA and iron dosing are notably lower
in Japan than in other countries.
In conclusion, in this short-term observational study
among representative Japanese HD patients following a new
ESA reimbursement policy that bundled rHuEPO into the
outpatient dialysis services payment since April 2006,
rHuEPO doses decreased and IV iron use increased, while
mean Hb values remained stable. Although the patterns
differed slightly by type of HD facility, the overall directions
of change (lower rHuEPO dose, greater IV iron use) were
consistent across facility type. Evaluation of the impact of
these changes in practice on clinical outcomes will require
longer-term follow-up. The need remains to identify ESA and
iron dosing strategies that optimize patient outcomes and
cost effectiveness.
METHODS
Data sources
The DOPPS is an observational study of HD patients randomly
selected from nationally representative facilities in 12 industrialized
countries. Detailed information on the sampling plan and study
methods has been described.31,32 Data for this analysis came from
JDOPPS3 (2005–2008). All patients were at least 18 years of age at
study enrollment.
Data collection
A total of 53 HD units from Japan were included for analysis. These
units had data from prevalent cross-sections of patients before and
after the date of change in rHuEPO reimbursement (1 April 2006).
The first cross-section had a median date of January 2006 (range 1
November 2005 to 27 February 2006) and included 1584 patients.
The second cross-section had a median date of January 2007 (range
1 November 2006 to 27 February 2007) and included 1622 patients.
Patients who were in the first cross-section, but had left the study
before the second cross-section, were replaced by randomly selected
patients new to the dialysis facility since the time of the first cross-
section. Patient information was collected without identifiers in
order to maintain patient anonymity. Informed consent was
obtained for each sampled patient as required from local or national
ethics committees or institutional review board. Patient data on
rHuEPO dosing, IV iron dosing, and laboratory values were
abstracted from patient records every 4 months by a nurse
coordinator in each HD unit. To simplify analysis, only patients
prescribed IV rHuEPO (Epoetin alfa or Epoetin beta) were included
in this study. Seven HD patients (0.2%) who were prescribed
subcutaneous rHuEPO and two HD patients on Darbepoetin alfa
(a long-acting ESA approved for use in Japan in July 2007) were
excluded. The rHuEPO use was defined as any use (yes/no) over the
most recent month. The rHuEPO dose (U per week) was calculated
as the average weekly dose over the most recent 4-week period.
IV iron use was defined as any use (yes/no) over the last 4 months.
IV iron dose (mg per month) was calculated as the average monthly
dose over the most recent 4 months.
The plausible rHuEPO dose range was set at 750–9000U per
week, with 9000U per week as the upper limit, because this is the
restricted maximum dose of rHuEPO in the Japanese system. A total
of 24 and 11 patients had rHuEPO doses either o750 or 49000U
per week, respectively. These patients were prescribed rHuEPO,
but their rHuEPO doses were set to missing, and they were not used
in the calculation of average weekly dose. For patients missing
reported TSAT, the measure was calculated as 100  serum iron/
total iron binding capacity, when these values were reported.
Trends from the first to second cross-section of Hb levels, serum
ferritin and TSAT levels, and treatment with rHuEPO and IV iron
were analyzed. Patient characteristics examined at each cross-section
included age, sex, HD vintage, and the 13 summary comorbidities
listed in Table 1. A patient was considered new to (incident) dialysis
if he or she entered the study within 30 days of their first-ever
dialysis treatment. Types of facility ownership considered in the
analysis were private clinics, private hospitals, and public hospitals.
Statistical analysis
Descriptive statistics at each cross-section were used to report
differences over time in treatment and laboratory values. Linear
mixed models were used to test for differences in continuous
variables (for example, Hb levels) between the cross-sections, and
accounted for the correlation between patients present in both
cross-sections. Ratios (for example, percentage medication use) were
compared between the cross-sections using a w2-test. All statistical
analyses were performed with SAS version 9.2 (SAS Institute,
Cary, NC).
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